Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study – IL PSO (Italian landscape psoriasis)
Purpose Tildrakizumab is a selective inhibitor of IL-23 approved for the treatment of moderate-to-severe plaque psoriasis in two dosages. We conducted a 16-week multicenter retrospective study to compare the effectiveness and safety of tildrakizumab 200 mg versus tildrakizumab 100 mg in patients wit...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2024.2350760 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850249992964407296 |
|---|---|
| author | Luigi Gargiulo Luciano Ibba Ruggero Cascio Ingurgio Piergiorgio Malagoli Fabrizio Amoruso Anna Balato Federico Bardazzi Pina Brianti Giovanna Brunasso Martina Burlando Anna E. Cagni Marzia Caproni Carlo G. Carrera Andrea Carugno Francesco Caudullo Aldo Cuccia Paolo Dapavo Eugenia V. Di Brizzi Valentina Dini Francesca M. Gaiani Paolo Gisondi Claudio Guarneri Claudia Lasagni Gaetano Licata Francesco Loconsole Angelo V. Marzano Matteo Megna Santo R. Mercuri Maria L. Musumeci Diego Orsini Simone Ribero Valentina Ruffo Di Calabria Francesca Satolli Davide Strippoli Massimo Travaglini Emanuele Trovato Marina Venturini Leonardo Zichichi Mario Valenti Antonio Costanzo Alessandra Narcisi |
| author_facet | Luigi Gargiulo Luciano Ibba Ruggero Cascio Ingurgio Piergiorgio Malagoli Fabrizio Amoruso Anna Balato Federico Bardazzi Pina Brianti Giovanna Brunasso Martina Burlando Anna E. Cagni Marzia Caproni Carlo G. Carrera Andrea Carugno Francesco Caudullo Aldo Cuccia Paolo Dapavo Eugenia V. Di Brizzi Valentina Dini Francesca M. Gaiani Paolo Gisondi Claudio Guarneri Claudia Lasagni Gaetano Licata Francesco Loconsole Angelo V. Marzano Matteo Megna Santo R. Mercuri Maria L. Musumeci Diego Orsini Simone Ribero Valentina Ruffo Di Calabria Francesca Satolli Davide Strippoli Massimo Travaglini Emanuele Trovato Marina Venturini Leonardo Zichichi Mario Valenti Antonio Costanzo Alessandra Narcisi |
| author_sort | Luigi Gargiulo |
| collection | DOAJ |
| description | Purpose Tildrakizumab is a selective inhibitor of IL-23 approved for the treatment of moderate-to-severe plaque psoriasis in two dosages. We conducted a 16-week multicenter retrospective study to compare the effectiveness and safety of tildrakizumab 200 mg versus tildrakizumab 100 mg in patients with a high disease burden or high body weight.Materials and methods Our retrospective study included 134 patients treated with tildrakizumab 200 mg and 364 patients treated with tildrakizumab 100 mg from 28 Italian Dermatology Units affected by moderate-to-severe plaque psoriasis. The patients had a body weight above 90 kg or a high disease burden (Psoriasis Area and Severity Index [PASI] ≥ 16 or the involvement of difficult-to-treat areas). We evaluated the effectiveness of tildrakizumab at the week-16 visit in terms of PASI90, PASI100 and absolute PASI ≤ 2.Results After 16 weeks of treatment with tildrakizumab 200 mg, PASI90 was reached by 57.5% of patients and PASI100 by 39.6% of patients. At the same time point, 34.3% and 24.2% of patients treated with tildrakizumab 100 mg achieved PASI90 and PASI100, respectively.Conclusions Our data suggest that tildrakizumab 200 mg has better effectiveness than tildrakizumab 100 mg in patients with a body weight ≥ 90 kg and a high disease burden. |
| format | Article |
| id | doaj-art-50011e4f4d42477e96cf16f9d602b59b |
| institution | OA Journals |
| issn | 0954-6634 1471-1753 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj-art-50011e4f4d42477e96cf16f9d602b59b2025-08-20T01:58:20ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532024-12-0135110.1080/09546634.2024.2350760Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study – IL PSO (Italian landscape psoriasis)Luigi Gargiulo0Luciano Ibba1Ruggero Cascio Ingurgio2Piergiorgio Malagoli3Fabrizio Amoruso4Anna Balato5Federico Bardazzi6Pina Brianti7Giovanna Brunasso8Martina Burlando9Anna E. Cagni10Marzia Caproni11Carlo G. Carrera12Andrea Carugno13Francesco Caudullo14Aldo Cuccia15Paolo Dapavo16Eugenia V. Di Brizzi17Valentina Dini18Francesca M. Gaiani19Paolo Gisondi20Claudio Guarneri21Claudia Lasagni22Gaetano Licata23Francesco Loconsole24Angelo V. Marzano25Matteo Megna26Santo R. Mercuri27Maria L. Musumeci28Diego Orsini29Simone Ribero30Valentina Ruffo Di Calabria31Francesca Satolli32Davide Strippoli33Massimo Travaglini34Emanuele Trovato35Marina Venturini36Leonardo Zichichi37Mario Valenti38Antonio Costanzo39Alessandra Narcisi40Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, ItalyDermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, ItalyDermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, ItalyDepartment of Dermatology, Dermatology Unit Azienda Ospedaliera San Donato Milanese, Milan, ItalyDermatology Unit, Azienda Ospedaliera di Cosenza, Cosenza, ItalyDermatology Unit, University of Campania L. Vanvitelli, Naples, ItalyDermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ItalyDermatology and Cosmetology Unit, IRCCS San Raffaele Hospital, Milan, ItalyDermatology Department, Galliera Hospital, Genoa, ItalyDepartment of Dermatology, Dipartimento di Scienze della Salute (DISSAL), University of Genoa, IRCCS Ospedale Policlinico San Martino, Genoa, ItalyUnità Operativa Dipartimentale di Dermatologia e Venereologia, IRCCS San Gerardo, Milan, ItalyImmunopathology and Rare Skin Diseases Unit, Section of Dermatology, Department of Health Sciences, Azienda Unità Sanitaria Locale Toscana Centro, University of Florence, Florence, ItalyDermatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalyDermatology Unit, ASST Papa Giovanni XXIII Hospital, Bergamo, ItalyDermatology Clinic, University of Catania, Catania, ItalyUnit of Dermatology, San Donato Hospital, Arezzo, ItalyDepartment of Biomedical Science and Human Oncology, Second Dermatologic Clinic, University of Turin, Turin, ItalyDermatology Unit, University of Campania L. Vanvitelli, Naples, ItalyDepartment of Dermatology, University of Pisa, Pisa, ItalyDepartment of Dermatology, Dermatology Unit Azienda Ospedaliera San Donato Milanese, Milan, ItalyUniversity of Verona, Verona, ItalyDepartment of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, ItalyDermatological Clinic, Department of Specialized Medicine, University of Modena, Modena, ItalyU.O.C. Dermatology Unit, "S. Antonio Abate" Hospital, Trapani, ItalyDepartment of Dermatology, University of Bari, Bari, ItalyDermatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalySection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, ItalyDermatology and Cosmetology Unit, IRCCS San Raffaele Hospital, Milan, ItalyDermatology Clinic, University of Catania, Catania, ItalyUOC Clinical Dermatology, Dermatological Institute S. Gallicano, IRCCS, Rome, ItalyDepartment of Biomedical Science and Human Oncology, Second Dermatologic Clinic, University of Turin, Turin, ItalyImmunopathology and Rare Skin Diseases Unit, Section of Dermatology, Department of Health Sciences, Azienda Unità Sanitaria Locale Toscana Centro, University of Florence, Florence, ItalyUnit of Dermatology, University of Parma, Parma, ItalyDermatology Unit, ASST Lecco, Alessandro Manzoni Hospital, Lecco, ItalyU.O.S.D. dermatologica – centro per la cura della psoriasi, Ospedale Perrino, Brindisi, ItalyUnit of Dermatology, Department of Medical, Surgical and Neurological Sciences, University of Siena, Siena, ItalyDermatology Department, University of Brescia, ASST Spedali Civili of Brescia, Brescia, ItalyU.O.C. Dermatology Unit, "S. Antonio Abate" Hospital, Trapani, ItalyDermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, ItalyDermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, ItalyDermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, ItalyPurpose Tildrakizumab is a selective inhibitor of IL-23 approved for the treatment of moderate-to-severe plaque psoriasis in two dosages. We conducted a 16-week multicenter retrospective study to compare the effectiveness and safety of tildrakizumab 200 mg versus tildrakizumab 100 mg in patients with a high disease burden or high body weight.Materials and methods Our retrospective study included 134 patients treated with tildrakizumab 200 mg and 364 patients treated with tildrakizumab 100 mg from 28 Italian Dermatology Units affected by moderate-to-severe plaque psoriasis. The patients had a body weight above 90 kg or a high disease burden (Psoriasis Area and Severity Index [PASI] ≥ 16 or the involvement of difficult-to-treat areas). We evaluated the effectiveness of tildrakizumab at the week-16 visit in terms of PASI90, PASI100 and absolute PASI ≤ 2.Results After 16 weeks of treatment with tildrakizumab 200 mg, PASI90 was reached by 57.5% of patients and PASI100 by 39.6% of patients. At the same time point, 34.3% and 24.2% of patients treated with tildrakizumab 100 mg achieved PASI90 and PASI100, respectively.Conclusions Our data suggest that tildrakizumab 200 mg has better effectiveness than tildrakizumab 100 mg in patients with a body weight ≥ 90 kg and a high disease burden.https://www.tandfonline.com/doi/10.1080/09546634.2024.2350760Biologicspsoriasispsoriasis treatmenttildrakizumab |
| spellingShingle | Luigi Gargiulo Luciano Ibba Ruggero Cascio Ingurgio Piergiorgio Malagoli Fabrizio Amoruso Anna Balato Federico Bardazzi Pina Brianti Giovanna Brunasso Martina Burlando Anna E. Cagni Marzia Caproni Carlo G. Carrera Andrea Carugno Francesco Caudullo Aldo Cuccia Paolo Dapavo Eugenia V. Di Brizzi Valentina Dini Francesca M. Gaiani Paolo Gisondi Claudio Guarneri Claudia Lasagni Gaetano Licata Francesco Loconsole Angelo V. Marzano Matteo Megna Santo R. Mercuri Maria L. Musumeci Diego Orsini Simone Ribero Valentina Ruffo Di Calabria Francesca Satolli Davide Strippoli Massimo Travaglini Emanuele Trovato Marina Venturini Leonardo Zichichi Mario Valenti Antonio Costanzo Alessandra Narcisi Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study – IL PSO (Italian landscape psoriasis) Journal of Dermatological Treatment Biologics psoriasis psoriasis treatment tildrakizumab |
| title | Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study – IL PSO (Italian landscape psoriasis) |
| title_full | Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study – IL PSO (Italian landscape psoriasis) |
| title_fullStr | Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study – IL PSO (Italian landscape psoriasis) |
| title_full_unstemmed | Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study – IL PSO (Italian landscape psoriasis) |
| title_short | Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study – IL PSO (Italian landscape psoriasis) |
| title_sort | comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight a 16 week multicenter retrospective study il pso italian landscape psoriasis |
| topic | Biologics psoriasis psoriasis treatment tildrakizumab |
| url | https://www.tandfonline.com/doi/10.1080/09546634.2024.2350760 |
| work_keys_str_mv | AT luigigargiulo comparativeeffectivenessoftildrakizumab200mgversustildrakizumab100mginpsoriaticpatientswithhighdiseaseburdenorabove90kgofbodyweighta16weekmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT lucianoibba comparativeeffectivenessoftildrakizumab200mgversustildrakizumab100mginpsoriaticpatientswithhighdiseaseburdenorabove90kgofbodyweighta16weekmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT ruggerocascioingurgio comparativeeffectivenessoftildrakizumab200mgversustildrakizumab100mginpsoriaticpatientswithhighdiseaseburdenorabove90kgofbodyweighta16weekmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT piergiorgiomalagoli comparativeeffectivenessoftildrakizumab200mgversustildrakizumab100mginpsoriaticpatientswithhighdiseaseburdenorabove90kgofbodyweighta16weekmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT fabrizioamoruso comparativeeffectivenessoftildrakizumab200mgversustildrakizumab100mginpsoriaticpatientswithhighdiseaseburdenorabove90kgofbodyweighta16weekmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT annabalato comparativeeffectivenessoftildrakizumab200mgversustildrakizumab100mginpsoriaticpatientswithhighdiseaseburdenorabove90kgofbodyweighta16weekmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT federicobardazzi comparativeeffectivenessoftildrakizumab200mgversustildrakizumab100mginpsoriaticpatientswithhighdiseaseburdenorabove90kgofbodyweighta16weekmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT pinabrianti comparativeeffectivenessoftildrakizumab200mgversustildrakizumab100mginpsoriaticpatientswithhighdiseaseburdenorabove90kgofbodyweighta16weekmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT giovannabrunasso comparativeeffectivenessoftildrakizumab200mgversustildrakizumab100mginpsoriaticpatientswithhighdiseaseburdenorabove90kgofbodyweighta16weekmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT martinaburlando comparativeeffectivenessoftildrakizumab200mgversustildrakizumab100mginpsoriaticpatientswithhighdiseaseburdenorabove90kgofbodyweighta16weekmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT annaecagni comparativeeffectivenessoftildrakizumab200mgversustildrakizumab100mginpsoriaticpatientswithhighdiseaseburdenorabove90kgofbodyweighta16weekmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT marziacaproni comparativeeffectivenessoftildrakizumab200mgversustildrakizumab100mginpsoriaticpatientswithhighdiseaseburdenorabove90kgofbodyweighta16weekmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT carlogcarrera comparativeeffectivenessoftildrakizumab200mgversustildrakizumab100mginpsoriaticpatientswithhighdiseaseburdenorabove90kgofbodyweighta16weekmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT andreacarugno comparativeeffectivenessoftildrakizumab200mgversustildrakizumab100mginpsoriaticpatientswithhighdiseaseburdenorabove90kgofbodyweighta16weekmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT francescocaudullo comparativeeffectivenessoftildrakizumab200mgversustildrakizumab100mginpsoriaticpatientswithhighdiseaseburdenorabove90kgofbodyweighta16weekmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT aldocuccia comparativeeffectivenessoftildrakizumab200mgversustildrakizumab100mginpsoriaticpatientswithhighdiseaseburdenorabove90kgofbodyweighta16weekmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT paolodapavo comparativeeffectivenessoftildrakizumab200mgversustildrakizumab100mginpsoriaticpatientswithhighdiseaseburdenorabove90kgofbodyweighta16weekmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT eugeniavdibrizzi comparativeeffectivenessoftildrakizumab200mgversustildrakizumab100mginpsoriaticpatientswithhighdiseaseburdenorabove90kgofbodyweighta16weekmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT valentinadini comparativeeffectivenessoftildrakizumab200mgversustildrakizumab100mginpsoriaticpatientswithhighdiseaseburdenorabove90kgofbodyweighta16weekmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT francescamgaiani comparativeeffectivenessoftildrakizumab200mgversustildrakizumab100mginpsoriaticpatientswithhighdiseaseburdenorabove90kgofbodyweighta16weekmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT paologisondi comparativeeffectivenessoftildrakizumab200mgversustildrakizumab100mginpsoriaticpatientswithhighdiseaseburdenorabove90kgofbodyweighta16weekmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT claudioguarneri comparativeeffectivenessoftildrakizumab200mgversustildrakizumab100mginpsoriaticpatientswithhighdiseaseburdenorabove90kgofbodyweighta16weekmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT claudialasagni comparativeeffectivenessoftildrakizumab200mgversustildrakizumab100mginpsoriaticpatientswithhighdiseaseburdenorabove90kgofbodyweighta16weekmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT gaetanolicata comparativeeffectivenessoftildrakizumab200mgversustildrakizumab100mginpsoriaticpatientswithhighdiseaseburdenorabove90kgofbodyweighta16weekmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT francescoloconsole comparativeeffectivenessoftildrakizumab200mgversustildrakizumab100mginpsoriaticpatientswithhighdiseaseburdenorabove90kgofbodyweighta16weekmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT angelovmarzano comparativeeffectivenessoftildrakizumab200mgversustildrakizumab100mginpsoriaticpatientswithhighdiseaseburdenorabove90kgofbodyweighta16weekmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT matteomegna comparativeeffectivenessoftildrakizumab200mgversustildrakizumab100mginpsoriaticpatientswithhighdiseaseburdenorabove90kgofbodyweighta16weekmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT santormercuri comparativeeffectivenessoftildrakizumab200mgversustildrakizumab100mginpsoriaticpatientswithhighdiseaseburdenorabove90kgofbodyweighta16weekmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT marialmusumeci comparativeeffectivenessoftildrakizumab200mgversustildrakizumab100mginpsoriaticpatientswithhighdiseaseburdenorabove90kgofbodyweighta16weekmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT diegoorsini comparativeeffectivenessoftildrakizumab200mgversustildrakizumab100mginpsoriaticpatientswithhighdiseaseburdenorabove90kgofbodyweighta16weekmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT simoneribero comparativeeffectivenessoftildrakizumab200mgversustildrakizumab100mginpsoriaticpatientswithhighdiseaseburdenorabove90kgofbodyweighta16weekmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT valentinaruffodicalabria comparativeeffectivenessoftildrakizumab200mgversustildrakizumab100mginpsoriaticpatientswithhighdiseaseburdenorabove90kgofbodyweighta16weekmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT francescasatolli comparativeeffectivenessoftildrakizumab200mgversustildrakizumab100mginpsoriaticpatientswithhighdiseaseburdenorabove90kgofbodyweighta16weekmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT davidestrippoli comparativeeffectivenessoftildrakizumab200mgversustildrakizumab100mginpsoriaticpatientswithhighdiseaseburdenorabove90kgofbodyweighta16weekmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT massimotravaglini comparativeeffectivenessoftildrakizumab200mgversustildrakizumab100mginpsoriaticpatientswithhighdiseaseburdenorabove90kgofbodyweighta16weekmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT emanueletrovato comparativeeffectivenessoftildrakizumab200mgversustildrakizumab100mginpsoriaticpatientswithhighdiseaseburdenorabove90kgofbodyweighta16weekmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT marinaventurini comparativeeffectivenessoftildrakizumab200mgversustildrakizumab100mginpsoriaticpatientswithhighdiseaseburdenorabove90kgofbodyweighta16weekmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT leonardozichichi comparativeeffectivenessoftildrakizumab200mgversustildrakizumab100mginpsoriaticpatientswithhighdiseaseburdenorabove90kgofbodyweighta16weekmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT mariovalenti comparativeeffectivenessoftildrakizumab200mgversustildrakizumab100mginpsoriaticpatientswithhighdiseaseburdenorabove90kgofbodyweighta16weekmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT antoniocostanzo comparativeeffectivenessoftildrakizumab200mgversustildrakizumab100mginpsoriaticpatientswithhighdiseaseburdenorabove90kgofbodyweighta16weekmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT alessandranarcisi comparativeeffectivenessoftildrakizumab200mgversustildrakizumab100mginpsoriaticpatientswithhighdiseaseburdenorabove90kgofbodyweighta16weekmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis |